KEYNOTE‑522: Phase 3 study of pembrolizumab + chemotherapy vs. placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs. placebo as adjuvant treatment for early-stage high-risk triple-negative breast cancer (TNBC). San Antonio Breast Cancer Symposium 2021; - Schmid, P; Cortes, J; Dent, R
GS1-01